Figure 1B (repeat 3 times)

Trial 1

BxPC-3						
Tat-SP4	-	10 µM	20 µM	-	10 µM	20 µM
CQ (50 µM)	-	-	-	+	+	+

p62	52

| LC3-I | 16 |
| LC3-II | 14 |

β-actin	43

Trial 2

BxPC-3						
Tat-SP4	-	10 µM	20 µM	-	10 µM	20 µM
CQ (50 µM)	-	-	-	+	+	+

p62	52

| LC3-I | 16 |
| LC3-II | 14 |

β-actin	43

Trial 3

BxPC-3						
Tat-SP4	-	10 µM	20 µM	-	10 µM	20 µM
CQ (50 µM)	-	-	-	+	+	+

p62	52

| LC3-I | 16 |
| LC3-II | 14 |

β-actin	43

Figure 1D (repeat 3 times)

Trial 1

MIA PaCa-2
Tat-SP4   -   10 μM   20 μM   -   10 μM   20 μM
CQ (5 μM)   -   -   -   +   +   +

p62 ——————————————————————————— 52

LC3-I ———————————————————————— 16
LC3-II ——————————————————————— 14

β-actin ———————————————————————— 43

Trial 2

MIA PaCa-2
Tat-SP4   -   10 μM   20 μM   -   10 μM   20 μM
CQ (5 μM)   -   -   -   +   +   +

p62 ——————————————————————————— 52

LC3-I ———————————————————————— 16
LC3-II ——————————————————————— 14

β-actin ———————————————————————— 43

Trial 3

MIA PaCa-2
Tat-SP4   -   10 μM   20 μM   -   10 μM   20 μM
CQ (5 μM)   -   -   -   +   +   +

p62 ——————————————————————————— 52

LC3-I ———————————————————————— 16
LC3-II ——————————————————————— 14

β-actin ———————————————————————— 43

Figure 1F (repeat 3 times)

Trial 1

PANC-1						
Tat-SP4	-	10 µM	20 µM	-	10 µM	20 µM
CQ (5 µM)	-	-	-	+	+	+

p62 — 52

LC3-I — 16
LC3-II — 14

β-actin — 43

Trial 2

PANC-1						
Tat-SP4	-	10 µM	20 µM	-	10 µM	20 µM
CQ (5 µM)						

p62 — 52

LC3-I — 16
LC3-II — 14

β-actin — 43

Trial 3

PANC-1						
Tat-SP4	-	10 µM	20 µM	-	10 µM	20 µM
CQ (5 µM)	-	-	-	+	+	+

p62 — 52

LC3-I — 16
LC3-II — 14

β-actin — 43

Figure 2A (repeat 3 times)

Trial 1

BxPC-3	Control	Tat-SP4(20 µM)
EGF(hour)	0 1 2 3 4 6	0 1 2 3 4 6

EGFR — 170

β-actin — 43

Trial 2

BxPC-3	Control	Tat-SP4(20 µM)
EGF(hour)	0 1 2 3 4 6	0 1 2 3 4 6

EGFR — 170

β-actin — 43

Trial 3

BxPC-3	Control	Tat-SP4(20 µM)
EGF(hour)	0 1 2 3 4 6	0 1 2 3 4 6

EGFR — 170

β-actin — 43

Figure 2C (repeat 3 times)

Trial 1

MIA PaCa-2 — Control — Tat-SP4(20 µM)

EGF(hour) 0 1 2 4 6 8 0 1 2 4 6 8

EGFR   170

β-actin   43

Trial 2

MIA PaCa-2 — Control — Tat-SP4(20 µM)

EGF(hour) 0 1 2 4 6 8   0 1 2 4 6 8

EGFR   170

β-actin   43

Trial 3

MIA PaCa-2 — Control — Tat-SP4(20 µM)

EGF(hour) 0 1 2 4 6 8 0 1 2 4 6 8

EGFR   170

β-actin   43

Figure 2E (repeat 3 times)

Trial 1

PANC-1   Control   Tat-SP4(30 µM)

EGF(hour)   0   2   4   6   8   12   0   2   4   6   8   12

EGFR   170

β-actin   43

Trial 2

PANC-1   Control   Tat-SP4(30 µM)

EGF(hour)   0   2   4   6   8   12   0   2   4   6   8   12

EGFR   170

β-actin   43

Trial 3

PANC-1   Control   Tat-SP4(30 µM)

EGF(hour)   0   2   4   6   8   12   0   2   4   6   8   12

EGFR   170

β-actin   43